Abstract:ABSTRACT The transcription of interferon-stimulated genes (ISGs) is classically triggered via activation of the JAK-STAT pathway, and together, ISGs raise a multifaceted antiviral barrier. An increasing body of evidence reports the existence of additional, non-canonical pathways and transcription factors that coordinate ISG expression. Detailed knowledge of how heterogenous mechanisms regulate ISG expression is crucial for the rational design of drugs targeting the type I interferon response. Here, we characterize the first ETS transcription factor family member as a regulator of non-canonical ISG expression: E74-like ETS transcription factor 1 (ELF1). Using high-content microscopy to quantify viral infection over time, we found that ELF1, itself an ISG, inhibits eight diverse RNA and DNA viruses uniquely at multi-cycle replication. ELF1 did not regulate expression of type I or II interferons, and ELF1’s antiviral effect was not abolished by the absence of STAT1 or by inhibition of JAK phosphorylation. Accordingly, comparative expression analyses by RNAseq revealed that the ELF1 transcriptional program is distinct from, and delayed with respect to, the immediate interferon response. Finally, knockdown experiments demonstrated that ELF1 is a critical component of the antiviral interferon response in vitro and in vivo. Our findings reveal a previously overlooked mechanism of non-canonical ISG regulation that both amplifies and prolongs the initial interferon response by expressing broadly antiviral restriction factors. AUTHOR SUMMARY Over 60 years after their discovery, we still struggle to understand exactly how interferons inhibit viruses. Our gap in knowledge stems, on one hand, from the sheer number of interferon-stimulated effector genes, of which only few have been characterized in mechanistic detail. On the other hand, our knowledge of interferon-regulated gene transcription is constantly evolving. We know that different regulatory mechanisms greatly influence the quality, magnitude, and timing of interferon-stimulated gene expression, all of which may contribute to the antiviral mechanism of interferons. Deciphering these regulatory mechanisms is indispensable for understanding this critical first line of host defense, and for harnessing the power of interferons in novel antiviral therapies. Here, we report a novel mechanism of interferon-induced gene regulation by an interferon-stimulated gene, which, paradoxically, inhibits viruses in the absence of additional interferon signaling: E74-like ETS transcription factor 1 (ELF1) raises an unusually delayed antiviral program that potently restricts propagation of all viruses tested in our study. Reduced levels of ELF1 significantly diminished interferon-mediated host defenses against influenza A virus in vitro and in vivo, suggesting a critical but previously overlooked role in the type I interferon response. The transcriptional program raised by ELF1 is vast and comprises over 400 potentially antiviral genes, which are almost entirely distinct from those known to be induced by interferon. Taken together, our data provide evidence for a critical secondary wave of antiviral protection that adds both “quality” and “time” to the type I interferon response.

Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon production

The canonical antiviral protein oligoadenylate synthetase 1 elicits antibacterial functions by enhancing IRF1 translation

The Oligoadenylate Synthetase-Like Protein Enhances Cellular Antiviral Activity Through RIG-I Pathway (68.3)

XAF1 Protects Host Against RNA Viruses&nbsp;by Stabilizing IRF1-Dependent Antiviral Immunity

Antiviral Activity of Human OASL Protein is Mediated by Enhancing Signaling of the RIG-I RNA Sensor

An Interferon Regulated MicroRNA Provides Broad Cell-Intrinsic Antiviral Immunity through Multihit Host-Directed Targeting of the Sterol Pathway

The large form of human 2',5'-Oligoadenylate Synthetase (OAS3) exerts antiviral effect against Chikungunya virus

Broad-spectrum RNA antiviral inspired by ISG15-/- deficiency

An ATP-Binding Cassette Transporter Gene Links Innate and Adaptive Immune Responses

Antiviral activity of human oligoadenylate synthetases-like (OASL) is mediated by enhancing retinoic acid-inducible gene I (RIG-I) signaling

Oligoadenylate-Synthetase-Family Protein OASL Inhibits Activity of the DNA Sensor Cgas During DNA Virus Infection to Limit Interferon Production.

RNA regulation of the antiviral protein 2′‐5′‐oligoadenylate synthetase

Interferon-Stimulated Genes that Target Retrovirus Translation

OAS1 suppresses African swine fever virus replication by recruiting TRIM21 to degrade viral major capsid protein

OASL suppresses infectious bursal disease virus replication by targeting VP2 for degrading through the autophagy pathway

Induction and suppression of antiviral RNA interference by influenza A virus in mammalian cells

Exploiting the Achilles’ Heel of Viral RNA Processing to Develop Novel Antivirals

Nuclear RNAi Modulates Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

The regulatory factor ELF1 triggers a critical wave of transcription in the antiviral response to type I interferon

Anti-viral defence by an mRNA ADP-ribosyltransferase that blocks translation

Anti-viral defense by an ADP-ribosyltransferase that targets mRNA to block translation